ZA201200112B - Melanocortin receptor-specific peptides - Google Patents

Melanocortin receptor-specific peptides

Info

Publication number
ZA201200112B
ZA201200112B ZA2012/00112A ZA201200112A ZA201200112B ZA 201200112 B ZA201200112 B ZA 201200112B ZA 2012/00112 A ZA2012/00112 A ZA 2012/00112A ZA 201200112 A ZA201200112 A ZA 201200112A ZA 201200112 B ZA201200112 B ZA 201200112B
Authority
ZA
South Africa
Prior art keywords
melanocortin receptor
specific peptides
peptides
melanocortin
receptor
Prior art date
Application number
ZA2012/00112A
Other languages
English (en)
Inventor
Yi-Qun Shi
Shubh D Sharma
John H Dodd
Wei Yang
Xin Chen
Original Assignee
Palatin Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palatin Technologies Inc filed Critical Palatin Technologies Inc
Publication of ZA201200112B publication Critical patent/ZA201200112B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA2012/00112A 2009-06-08 2012-01-07 Melanocortin receptor-specific peptides ZA201200112B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18492909P 2009-06-08 2009-06-08
PCT/US2010/037589 WO2010144344A2 (en) 2009-06-08 2010-06-07 Melanocortin receptor-specific peptides

Publications (1)

Publication Number Publication Date
ZA201200112B true ZA201200112B (en) 2013-06-26

Family

ID=43309425

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/00112A ZA201200112B (en) 2009-06-08 2012-01-07 Melanocortin receptor-specific peptides

Country Status (14)

Country Link
US (4) US8846601B2 (enExample)
EP (1) EP2440227B1 (enExample)
JP (1) JP5805632B2 (enExample)
KR (1) KR101726893B1 (enExample)
CN (2) CN102458436B (enExample)
AU (1) AU2010259008C1 (enExample)
BR (1) BRPI1009644B1 (enExample)
CA (1) CA2761607C (enExample)
EA (1) EA020959B1 (enExample)
IL (1) IL216843A (enExample)
MX (1) MX2011013117A (enExample)
NZ (1) NZ596617A (enExample)
WO (1) WO2010144344A2 (enExample)
ZA (1) ZA201200112B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010144344A2 (en) * 2009-06-08 2010-12-16 Palatin Technologies, Inc. Melanocortin receptor-specific peptides
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
AU2010321738B2 (en) * 2009-11-23 2016-07-14 Palatin Technologies, Inc. Melanocortin-1 receptor-specific cyclic peptides
CA2825098C (en) 2011-01-27 2020-03-10 Universite De Montreal Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators
HRP20211950T1 (hr) 2011-12-29 2022-03-18 Rhythm Pharmaceuticals, Inc. Postupak liječenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima
US9284283B2 (en) 2012-02-02 2016-03-15 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating IL-17
EP2970388B1 (en) 2013-03-15 2018-07-25 Rhythm Pharmaceuticals, Inc. Peptide compositions
JP6538025B2 (ja) * 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物
WO2015162287A1 (en) * 2014-04-25 2015-10-29 Phi Pharma Sa Keratan sulfate specific transporter molecules
CN104436159A (zh) * 2014-12-09 2015-03-25 天津医科大学眼科医院 一种新型滴眼液对治疗干眼的用途
WO2016168388A2 (en) * 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
SG10202101510XA (en) 2015-09-30 2021-03-30 Rhythm Pharmaceuticals Inc Method of treating melanocortin-4 receptor pathway-associated disorders
CN110461861B (zh) * 2016-11-09 2024-11-15 南洋理工大学 人参肽和人参肽类似肽的制备和利用
MX2020009900A (es) * 2018-03-23 2021-01-08 Palatin Technologies Inc Formulaciones peptidicas especificas para el receptor de melanocortinas y metodos para un suministro especifico en el tubo gastrointestinal.
EP3773897A1 (en) 2018-04-06 2021-02-17 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
JP7817168B2 (ja) * 2020-02-03 2026-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジアミン連結受容体特異的環状ペプチド
EP4100042A4 (en) * 2020-02-03 2024-04-10 Palatin Technologies, Inc. Reverse amide-linked melanocortin receptor-specific cyclic peptides
CN114890958B (zh) * 2022-02-23 2023-10-20 四川警察学院 双光子染料化合物、其制备方法及其应用
CN115521356B (zh) * 2022-08-17 2024-04-02 桂林医学院 一种具有美白功效的多肽及其应用
CN119529031B (zh) * 2024-11-27 2025-12-05 润辉生物技术（威海）有限公司 一种环肽衍生物及其制备方法与应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
JP3219096B2 (ja) 1990-05-10 2001-10-15 ニコメド ファーマ エイエス ｎ―グリコフロール類及びｎ―エチレングリコール類を含有する医薬製剤
US6100048A (en) 1992-04-10 2000-08-08 Oregon Health Sciences University Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
US5977070A (en) 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US7396814B2 (en) 1995-06-07 2008-07-08 Palatin Technologies, Inc. Metallopeptide compositions for treatment of sexual dysfunction
EP0946595A2 (en) 1996-12-17 1999-10-06 Quadrant Holdings Cambridge Limited Melanocortins
ES2256898T3 (es) 1996-12-20 2006-07-16 Alza Corporation Composicion de gel y procedimientos.
US5908825A (en) 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
US6350430B1 (en) 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
US6193991B1 (en) 1997-10-29 2001-02-27 Atul J. Shukla Biodegradable delivery systems of biologically active substances
GB9808229D0 (en) 1998-04-17 1998-06-17 Quadrant Holdings Cambridge Melanocortin receptor ligands
SE9801571D0 (sv) 1998-05-05 1998-05-05 Wapharm Ab Melanokortin-1-receptorselektiva föreningar
GB9816234D0 (en) 1998-07-24 1998-09-23 William Harvey Research Limite Compounds for use in the treatment of inflammation
GB9827500D0 (en) 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
US6887846B2 (en) 1999-03-24 2005-05-03 Zengen, Inc. Antimicrobial amino acid sequences derived from alpha-melanocyte-stimulating hormone
ATE393783T1 (de) 1999-03-29 2008-05-15 Procter & Gamble Melanocortinrezeptor-liganden
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
US7235625B2 (en) * 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US6699873B1 (en) 1999-08-04 2004-03-02 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2001030808A1 (en) 1999-10-27 2001-05-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor-ligand binding
US20030064921A1 (en) 1999-10-27 2003-04-03 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
AU2001229491A1 (en) 2000-01-18 2001-07-31 Merck And Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor antagonists
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
WO2001085930A2 (en) 2000-05-09 2001-11-15 The Regents Of The University Of California Methods and compounds for modulating melanocortin receptor ligand binding and activity
GB0012370D0 (en) 2000-05-22 2000-07-12 Quadrant Holdings Cambridge Peptoids
WO2002018437A2 (en) * 2000-08-30 2002-03-07 F. Hoffmann-La Roche Ag Cyclic peptides having melanocortin-4 receptor agonist activity
PL362003A1 (en) 2000-09-27 2004-10-18 The Procter & Gamble Company Melanocortin receptor ligands
US7345144B2 (en) 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7342089B2 (en) 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
AU2002322466B2 (en) 2001-07-11 2007-08-30 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
EP1409521A2 (en) 2001-07-12 2004-04-21 Merck & Co., Inc. Cyclic peptides as potent and selective melanocortin-4 receptor agonists
FR2835528B1 (fr) 2002-02-01 2004-03-12 Inst Europ Biolog Cellulaire Nouveaux derives peptidiques, leur preparation et leur application therapeutique et cosmetique
US7034004B2 (en) 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
AU2003248888A1 (en) 2002-07-09 2004-01-23 Palatin Technologies, Inc. Peptide composition for treatment of sexual dysfunction
US20060122121A1 (en) 2002-11-14 2006-06-08 Lipton James M Modified alpha-MSH peptides and derivatives thereof
US7135548B2 (en) 2002-11-14 2006-11-14 Zengen, Inc. Modified α-MSH peptides and derivatives thereof
CA2557520C (en) 2003-02-26 2011-09-13 Donald W. Landry A method for stabilizing blood pressure in hemodialysis subjects
MXPA05011830A (es) 2003-05-09 2006-01-26 Novo Nordisk As Peptidos para uso en el tratamiento de la obesidad.
EP1625158A2 (en) 2003-05-09 2006-02-15 Novo Nordisk A/S Peptides for use in treating obesity
EP1644023A2 (en) 2003-06-19 2006-04-12 Eli Lilly And Company Melanocortin recptor 4(mc4) agonists and their uses
WO2005000338A1 (en) 2003-06-19 2005-01-06 Eli Lilly And Company Uses of melanocortin-3 receptor (mc3r) agonist peptides
CN1809372A (zh) * 2003-06-19 2006-07-26 伊莱利利公司 黑皮质素受体4(mc4)激动剂及其用途
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
JP4754487B2 (ja) 2003-08-20 2011-08-24 エミスフィアー テクノロジーズ インコーポレイテッド グルカゴン様ペプチド（ｇｌｐ）−１化合物またはメラノコルチン４受容体（ｍｃ４）アゴニストペプチドの経口デリバリーのための化合物、方法および製剤
CN101497654A (zh) 2003-09-30 2009-08-05 诺沃挪第克公司 黑皮素受体激动剂
DK1689349T3 (da) 2003-11-24 2013-12-02 Clinuvel Pharmaceuticals Ltd Fremgangsmåde til induktion af melanogenese i mennesker med variante MC1R-alleler
WO2005060985A1 (en) 2003-12-10 2005-07-07 Merck & Co., Inc. Inhibition of voluntary ethanol consumption with selective melanocortin 4-receptor agonists
JP2007530674A (ja) 2004-03-29 2007-11-01 イーライ リリー アンド カンパニー 連続注入によって投与されるメラノコルチン−４受容体（ｍｃ４ｒ）アゴニストペプチドの使用
US9345911B2 (en) 2004-08-04 2016-05-24 Clinuvel Pharmaceuticals Limited Methods of inducing melanogenesis in a subject
BRPI0518411A2 (pt) 2004-10-25 2008-11-18 Centocor Inc mimeticorpos que se ligam a receptor de melanocortina, composiÇÕes, mÉtodos e usos
CN101052650A (zh) 2004-11-04 2007-10-10 诺和诺德公司 用于治疗肥胖的新颖的肽类
EP1809665A2 (en) 2004-11-04 2007-07-25 Novo Nordisk A/S Mc4r selective peptides and their use in the treatment of obesity
WO2006048451A1 (en) 2004-11-04 2006-05-11 Novo Nordisk A/S Peptides for use in the treatment of obesity
EP1809666A2 (en) 2004-11-04 2007-07-25 Novo Nordisk A/S Peptides for use in the treating obesity
EP1863841A1 (en) 2005-03-17 2007-12-12 Novo Nordisk A/S Compounds for use in the treatment of obesity
RU2439079C2 (ru) * 2005-07-08 2012-01-10 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик С.А.С. Лиганды рецепторов меланокортинов
AU2006269321A1 (en) 2005-07-08 2007-01-18 Ipsen Pharma S.A.S. Ligands of melanocortin receptors
CN101222942A (zh) 2005-07-18 2008-07-16 诺沃-诺迪斯克有限公司 用于治疗肥胖的肽
EP1957096A4 (en) 2005-08-29 2012-03-21 Palatin Technologies Inc CYCLIC PEPTIDE INSULATION BY SPRAY DRYING
US8114844B2 (en) * 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
WO2008025094A1 (en) 2006-08-31 2008-03-06 Clinuvel Pharmaceuticals Limited Method of treatment of photodermatoses
CN101177450A (zh) * 2006-11-09 2008-05-14 武汉聚奇医药科技有限公司 引发男性阴茎勃起和提高女性性欲的短肽
JP2010516652A (ja) 2007-01-18 2010-05-20 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
WO2008087188A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
US20100022446A1 (en) 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
JP2010517943A (ja) 2007-01-18 2010-05-27 ノボ・ノルデイスク・エー／エス 肥満の治療に使用される新規ペプチド
CN101302246B (zh) * 2007-05-09 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 黑色素皮质激素受体七肽类激动剂及其制备方法和用途
EP2167112A4 (en) 2007-06-15 2012-01-25 Ipsen Pharma Sas CYCLIC PEPTIDE MELANOCORTIN RECEPTOR LIGANDS
CA2952095C (en) 2007-11-05 2020-02-18 Ipsen Pharma S.A.S. Use of melanocortins to treat insulin sensitivity
JP5628796B2 (ja) * 2008-06-09 2014-11-19 パラティン テクノロジーズ, インコーポレイテッドPalatin Technologies, Inc. 性的不能の治療用のメラノコルチンレセプタ特異的ペプチド
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
WO2010144344A2 (en) * 2009-06-08 2010-12-16 Palatin Technologies, Inc. Melanocortin receptor-specific peptides

Also Published As

Publication number Publication date
WO2010144344A3 (en) 2011-02-03
AU2010259008B2 (en) 2014-12-04
JP5805632B2 (ja) 2015-11-04
US9458201B2 (en) 2016-10-04
US20120178701A1 (en) 2012-07-12
IL216843A0 (en) 2012-02-29
CN102458436B (zh) 2015-06-03
US8846601B2 (en) 2014-09-30
US10179804B2 (en) 2019-01-15
EP2440227A2 (en) 2012-04-18
CN102458436A (zh) 2012-05-16
AU2010259008A1 (en) 2011-11-24
EA020959B1 (ru) 2015-03-31
EA201190338A1 (ru) 2012-06-29
EP2440227A4 (en) 2013-03-20
BRPI1009644B1 (pt) 2022-02-08
MX2011013117A (es) 2012-05-23
JP2012529433A (ja) 2012-11-22
US10632171B2 (en) 2020-04-28
US20160318977A1 (en) 2016-11-03
KR20120092089A (ko) 2012-08-20
NZ596617A (en) 2014-04-30
BRPI1009644A2 (pt) 2020-06-23
IL216843A (en) 2016-11-30
EP2440227B1 (en) 2017-10-18
CA2761607A1 (en) 2010-12-16
WO2010144344A2 (en) 2010-12-16
AU2010259008C1 (en) 2016-04-21
US20190216887A1 (en) 2019-07-18
US20140357575A1 (en) 2014-12-04
CN105037502A (zh) 2015-11-11
CA2761607C (en) 2018-09-04
KR101726893B1 (ko) 2017-04-13

Similar Documents

Publication Publication Date Title
ZA201200128B (en) Melanocortin receptor-specific peptides
ZA201200112B (en) Melanocortin receptor-specific peptides
IL219947A0 (en) Melanocortin-1 receptor-specific cyclic peptides
IL219946A0 (en) Melanocortin-1 receptor-specific linear peptides
IL214365A0 (en) Antibiotic peptides
GB0914110D0 (en) Peptide libraries
AU331433S (en) Canister
GB2476465B (en) Recycling Technology
EP2480578A4 (en) MODIFICATION OF POLYPEPTIDE
GB0920981D0 (en) Peptides
ZA201108446B (en) FViII-DERIVED PEPTIDES
GB0918914D0 (en) Composite
ZA201203722B (en) Peptide
GB0921691D0 (en) Sophorolpid transporter protien
GB0901461D0 (en) Recycling
GB0920987D0 (en) Peptides
HK1169123A (en) Melanocortin receptor-specific peptides
GB0817978D0 (en) Peptides
GB0908570D0 (en) Key-boards
GB0911790D0 (en) Peptides
IL214496A0 (en) Short b-defensin-derived peptides
GB0909494D0 (en) Neuroprotective peptide
GB0810449D0 (en) Peptides
GB0812093D0 (en) Phylloseptin peptides
GB0815673D0 (en) Peptides